MX2013002511A - Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado. - Google Patents

Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Info

Publication number
MX2013002511A
MX2013002511A MX2013002511A MX2013002511A MX2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
cognitive impairment
mild cognitive
fused triazoles
Prior art date
Application number
MX2013002511A
Other languages
English (en)
Inventor
Tatsuki Koike
Takafumi Takai
Yasutaka Hoashi
Tetsuya Tsukamoto
Makoto Kamata
Minoru Nakamura
Yoshihide Tomata
Yuichi Kajita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013002511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2013002511A publication Critical patent/MX2013002511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un derivado heterocíclico que tiene una actividad inhibidora de producción de ß-amiIoide superior y/o una actividad de modulación de ?-secretasa superior, y su uso. Un compuesto representado por la fórmula (I): en donde cada símbolo es como se define en la presente especificación, o una sal del mismo.
MX2013002511A 2010-09-02 2011-09-01 Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado. MX2013002511A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
MX2013002511A true MX2013002511A (es) 2013-07-29

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002511A MX2013002511A (es) 2010-09-02 2011-09-01 Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Country Status (21)

Country Link
US (3) US8901309B2 (es)
EP (1) EP2611805A1 (es)
JP (1) JP5871909B2 (es)
KR (1) KR20130139895A (es)
CN (1) CN103249733A (es)
AR (1) AR082865A1 (es)
AU (1) AU2011296887A1 (es)
BR (1) BR112013004746A2 (es)
CA (1) CA2809779A1 (es)
CL (1) CL2013000575A1 (es)
DO (1) DOP2013000051A (es)
EA (1) EA201390333A1 (es)
EC (1) ECSP13012535A (es)
MA (1) MA34556B1 (es)
MX (1) MX2013002511A (es)
PE (1) PE20131305A1 (es)
SG (1) SG187917A1 (es)
TW (1) TW201213327A (es)
UY (1) UY33586A (es)
WO (1) WO2012029991A1 (es)
ZA (1) ZA201301929B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767764A1 (en) * 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
BR112013004746A2 (pt) * 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
US10442807B2 (en) * 2015-05-12 2019-10-15 Fmc Corporation Aryl substituted bicyclic compounds as herbicides
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005037832A2 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2005115990A1 (ja) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
CN100577657C (zh) 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US20090221611A1 (en) 2006-01-11 2009-09-03 Devita Robert J Fused Triazole Tachykinin Receptor Antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008078725A1 (ja) 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited チアゼピン誘導体
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
CA2767764A1 (en) * 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
BR112013004746A2 (pt) * 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."

Also Published As

Publication number Publication date
EP2611805A1 (en) 2013-07-10
CL2013000575A1 (es) 2013-08-23
PE20131305A1 (es) 2013-10-31
SG187917A1 (en) 2013-04-30
AR082865A1 (es) 2013-01-16
WO2012029991A1 (en) 2012-03-08
ECSP13012535A (es) 2013-06-28
CA2809779A1 (en) 2012-03-08
JP5871909B2 (ja) 2016-03-01
US20120059030A1 (en) 2012-03-08
MA34556B1 (fr) 2013-09-02
AU2011296887A1 (en) 2013-04-11
US20130178497A1 (en) 2013-07-11
DOP2013000051A (es) 2013-04-30
KR20130139895A (ko) 2013-12-23
UY33586A (es) 2012-03-30
JP2013536798A (ja) 2013-09-26
BR112013004746A2 (pt) 2016-06-07
CN103249733A (zh) 2013-08-14
US8901309B2 (en) 2014-12-02
TW201213327A (en) 2012-04-01
EA201390333A1 (ru) 2013-08-30
US8822699B2 (en) 2014-09-02
ZA201301929B (en) 2013-11-27
US20140350260A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MX2013006113A (es) Compuestos biciclico.
MX2013002511A (es) Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
TN2012000401A1 (en) Heterocyclic compound
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
MX360706B (es) Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
IN2015DN00827A (es)
IN2014CN04558A (es)
AU2012324805A8 (en) (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MY158982A (en) Heterocyclic compound
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
MY189098A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
GEP20156399B (en) Microbiocidal heterocycles
TN2013000074A1 (en) Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
IN2012DN02069A (es)
CR20130119A (es) Triazoles fundido para el tratamiento o profilaxis de deterioro cognitivo leve
TN2013000230A1 (en) Bicyclic compound
UA58679U (ru) 8-оксихинолиния нитробензоаты, которые проявляют противовоспалительную и антимикробную активность
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal